Research showed that in lung cancer, the proteasomal degradation of NRF2 protein promoted by the E3 ligase MIB1 could sensitize lung cancer cells to ferroptosis [12] and that the suppression of NRF2 expression and activity could be a novel approach to controlling LUAD clinically. The gene discussed is MIB1; the disease is lung carcinoma.